Inncardio, Inc. Announces Acquisition of Cengent Therapeutics, Inc.

Inncardio, Inc. Announces Acquisition of Cengent Therapeutics,
Inc. 


NEW YORK, April 1  /PRNewswire-FirstCall/ -- Inncardio, Inc. (OTC:INDO)
(BULLETIN BOARD: INDO) , a company founded by Bioaccelerate Holdings Inc.
(OTC:BACL) (BULLETIN BOARD: BACL) , announced today a definitive agreement to
acquire Cengent Therapeutics Inc., a privately held, structure-guided drug
discovery company based in San Diego, CA.  Inncardio, Inc. is a biotechnology
company focused on the development of treatments and therapies targeted at
cardiovascular-related diseases.

"We are pleased to have signed this agreement as we believe the combination of
the products we are developing and the technological expertise and lead
compounds identified by Cengent will extend and enhance our current product
development efforts," stated Bernard Ross, Chief Executive Officer of
Inncardio. "The acquisition represents a further execution of Bioaccelerate's
strategy to invest in the rapid development and value enhancement of promising
drug candidates, such as those being developed by Cengent."

"The acquisition by Inncardio provides us with significant additional resources
and access to the public capital markets as we continue to drive our product
candidates forward," said Gordon Foulkes, Ph.D., President of Cengent. "We
believe this is the best opportunity for Cengent, our shareholders and
employees. Inncardio provides the ability to preserve and grow Cengent's lead
diabetes compounds into the clinic and maximize their value. Cengent provides
capabilities in drug discovery, medicinal chemistry, preclinical development,
and bringing novel drugs into the clinic, complementing Inncardio's expanded
pipeline of products."

About Cengent Therapeutics, Inc.

Cengent Therapeutics is a structure-based drug discovery company with a primary
focus on compounds targeting signal transduction for the treatment of
obesity/diabetes. Cengent's recent development efforts have resulted in the
discovery of orally active PTP-1B inhibitors for treatment of type II diabetes
and obesity.

About Inncardio, Inc.

Inncardio, Inc., a company founded by Bioaccelerate Holdings Inc. (OTC:BACL)
(BULLETIN BOARD: BACL) , is a biotechnology company engaged in the acquisition,
development and commercialization of treatments and therapies targeted at
various metabolic diseases. The Company's management team is focused on both
the ongoing development of Inncardio's products to build value prior to
partnering and the in-licensing of additional cardiovascular products to
further enhance the Company's commercial value. The Company currently has six
compounds in its portfolio. The three lead programs are novel formulations of
approved drugs where, re-formulation is predicted to either improve efficacy or
minimize side effects.  The three other products are novel compounds and are in
pre-clinical development. Inncardio's lead development product is being
investigated for use as a post-stroke therapy that has a novel delivery profile
and is targeted to reduce the incidence and severity of ischemic deficits in
patients with subarachnoid hemorrhage from rupture intracranial berry aneurysm.

Bioaccelerate Safe Harbor Statement

Certain statements contained herein are "forward-looking" statements (as such
term is defined in the Private Securities Litigation Reform Act of 1995).
Because these statements include risks and uncertainties, actual results may
differ materially from those expressed or implied by such forward-looking
statements. Specifically, factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking statements
include, but are not limited to: risks associated with pre-clinical and
clinical developments in the biopharmaceutical industry in general and in
Inncardio or Bioaccelerate's compounds under development in particular; the
potential failure of Inncardio or Bioaccelerate's compounds under development
to prove safe and effective for treatment of disease; uncertainties inherent in
the early stage of Inncardio or Bioaccelerate's compounds under development;
failure to successfully implement or complete clinical trials; failure to
receive marketing clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or strategic
initiatives that change Inncardio or Bioaccelerate's business, structure or
projections; the development of competing products; uncertainties related to
Inncardio or Bioaccelerate's dependence on third parties and partners; and
those risks described in the filings with the SEC, all of which are under
Bioaccelerate's prior name Mobile Design Concepts, Inc. and Inncardio's prior
name Softwall Equipment Corp. Inncardio and Bioaccelerate disclaim any
obligation to update these forward-looking statements.

   CONTACT:
   Christopher O'Toole
   Senior Vice President
   Bioaccelerate Holdings Inc.
   212-332-4387

   Gordon Foulkes, Ph.D.
   President
   Cengent Therapeutics, Inc.
   858-675-2400


Inc.

DATASOURCE: Inncardio, Inc.; Bioaccelerate Holdings Inc.; Cengent Therapeutics,



CONTACT:  Christopher O'Toole, Senior Vice President, Bioaccelerate

Holdings Inc., [phone]; Gordon Foulkes, Ph.D., President, Cengent

Therapeutics, Inc., [phone]

Copyright